Open AccessNew Clues with Omalizumab for Broncho-Cutaneous Hyperresposiveness
Author(s) -
Erol Kilic
Publication year - 2016
Publication title -
the annals of clinical and analytical medicine
Language(s) - English
Resource type - Journals
ISSN - 2667-663X
DOI - 10.4328/jcam.3335
Subject(s) - medicine , omalizumab , dermatology , immunology , immunoglobulin e , antibody
We retrospectively retrieved our records and identified Five patients who had used Omalizumab due to allergic asthma and co-existent physical urticaria. Patients received Omalizumab at a dose of 150 to 300 mg/month for 16 weeks. DLQI was measured before and after three months of Omalizumab treatment. The beneficial effects of anti-IgE treatment observed in both allergic asthma and physical urticaria, as seen in our cases, suggests Ig E as a potential actor in the pathogenesis these disorders.